Beyond Federal Gates: How State-Level Deregulation Is Launching a Uniquely Commercial Frontier for Early-Stage Bio-Therapeutics
In a landmark divergence from federal medical oversight, a newly finalized state regulatory framework has opened the door for biotechnology companies to market unapproved experimental therapeutics directly to consumers. Under…
